Dolutegravir: A New HIV Integrase Inhibitor for the Treatment of HIV Infection

References

• Kitahata MM , GangeSJ , AbrahamAGet al. Effects of early versus deferred antiretroviral therapy for HIV on survival . N. Engl. J. Med.360 ( 18 ), 1815 – 1826 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents . What to start: initial combination regimens for the antiretroviral-naive patient. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services February 2013 . www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf .
   Google Scholar
• Craigie R . HIV integrase, a brief overview from chemistry to therapeutics . J. Biol. Chem.276 , 23213 – 23216 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hightower KE , WangR , DeAndaFet al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase-resistant HIV-1 integrase-DNA complexes . Antimicrob. Agents Chemother.55 ( 10 ), 4552 – 4559 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hare S , SmithSJ , MetifiotMet al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) . Mol. Pharmacol.80 ( 4 ), 565 – 572 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Min S , SloanL , DeJesusEet al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as a 10-day monotherapy in HIV-1-infected adults . AIDS25 , 1737 – 1745 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Min S , SongI , BorlandJet al. Pharmacokinetics and safety of S/GSK1349572, a next generation HIV integrase inhibitor, in healthy volunteers . Antimicrob. Agents Chemother.54 ( 1 ), 254 – 258 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• van Lunzen J , MaggioloF , ArribasJRet al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, Phase 2b trial . Lancet Infect. Dis.12 ( 2 ), 111 – 118 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Song I , BorlandJ , ChenSet al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir . Antimicrob. Agents Chemother.56 ( 3 ), 1627 – 1629 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Tivicay US Prescribing Information . ViiV Healthcare, Research Triangle Park, NC 27709, August 2013 . www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf .
   Google Scholar
• Letendre S , MillsA , TashimaKet al. ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1 infected, ART-naive subjects . Clin. Infect. Dis.59 ( 7 ), 1032 – 1037 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Castellino S , MossL , WagnerDet al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans . Antimicrob. Agents Chemother.57 ( 8 ), 3536 – 3546 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Reese MJ , SavinaPM , GenerauxGTet al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor . Drug Metab. Dispos.41 , 353 – 361 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Weller S , BorlandJ , ChenSet al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment . Eur. J. Clin. Pharmacol.70 ( 1 ), 29 – 35 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Viani R , AlveroC , FentonTet al. Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-week Results . Presented at : 21st Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA , 3–6 March, 2014 ( Abstract LB-2788 ).
   Google Scholar
• Viani R , AlveroC , FentonTet al. Safety Pharmacokinetics and Efficacy of Dolutegravir Treatment Experienced HIV+ Children . Presented at : 21st Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA , 3–6 March 2014 ( Abstract 119 ).
   Google Scholar
• Recommendations on integrase inhibitor use in antiretroviral treatment-naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents . www.aidsinfo.nih.gov .
   Google Scholar
• Walmsley SL , AntelaA , ClumeckNet al. Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection . N. Engl. J. Med.369 ( 19 ), 1807 – 1818 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lennox JL , DeJesusE , LazzarinAet al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicenter, double-blind randomised controlled trial . Lancet374 , 796 – 806 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• JeJesus E , RockstrohJK , HenryKet al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumerate for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3, non-inferiority trial . Lancet379 , 2429 – 2438 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Walmsley S , BerenguerJ , Khuong-JossesMet al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE Study (ING114467) . Presented at : 21st Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA , 3–6 March 2014 ( Abstract 543 ).
   Google Scholar
• Raffi F , RachlisA , StellbrinkHet al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study . Lancet381 , 735 – 743 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Raffi F , JaegerH , Quiros-RoldanEet al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial . Lancet Infect. Dis.13 ( 11 ), 927 – 935 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Clotet B , FeinbergJ , Van LunzenJet al. Once-daily dolutegravir versus daruanvir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study . Lancet383 ( 9936 ), 2222 – 2231 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cahn P , PozniakA , MingroneHet al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study . Lancet382 ( 9893 ), 700 – 708 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Castagna A , MaggioloF , PencoG , WrightD , MillsAet al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study . J. Infect. Dis.210 ( 3 ), 354 – 362 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Eron JJ , ClotetB , DurantJet al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study . J. Infect. Dis.207 , 740 – 748 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kobayashi M , YoshinagaT , SekiTet al. In vitro antiretroviral properties of S/GSK1349572, a next generation HIV integrase inhibitor . Antimicrob. Agents Chemother.55 , 813 – 821 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Underwood MR , JohnsBA , SatoAet al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults . J. Acquir. Immune Defic. Syndr.61 ( 3 ), 297 – 301 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Quashie PK , MespledeT , HanYSet al. Characterization of the R263K mutation in the HIV-1 integrase strand transfer inhibitor dolutegravir . J. Virol.86 , 2696 – 2705 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mesplede T , OsmanN , WaresMet al. Addition of the E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity . J. Antimicrob. Chemother.69 ( 10 ), 2733 – 2740 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Stellbrink H-J , ReynesJ , LazzarinAet al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study . AIDS27 , 1771 – 1778 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ford SL , GouldE , ChenSet al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744 . Antimicrob. Agents Chemother.57 ( 11 ), 5472 – 5477 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Song I , BorlandJ , MinSet al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir . Antimicrob. Agents Chemother.55 ( 7 ), 3517 – 3521 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Song I , BorlandJ , ChenSet al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572 . Br. J. Clin. Pharmacol.72 ( 1 ), 103 – 108 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Song I , MinS , BorlandJet al. The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants . J. Clin. Pharmacol.51 , 237 – 242 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Song I , BorlandJ , ChenSet al. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir . Eur. J. Clin. Pharmacol.70 ( 10 ), 1173 – 1179 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Song I , BorlandJ , ChenSet al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects . Antimicrob. Agents Chemother. doi: 10.1128/AAC.03282-14 ( 2014 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Song I , MarkS , ChenSet al. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects . Drug Alcohol Depend.13 , 325 – 326 ( 2013 ).
   Google Scholar
• Dooley KE , SayreP , BorlandJet al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase1 study among healthy subjects . J. Acquir. Immune Defic. Syndr.62 ( 1 ), 21 – 27 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Patel P , SongI , BorlandJet al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers . J. Antimicrob. Chemother.66 , 1567 – 1572 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Weller S , ChenS , BorlandJ , SavinaP , WynneB , PiscitelliS . Bioequivalence of a dolutegravir, abacavir and lamivudine fixed-dose combination tablet and the effect of food . J. Acquir. Immune Defic. Syndr.66 ( 4 ), 393 – 398 ( 2014 ).
   PubMed Web of Science ®Google Scholar